A Phase I Study of RO7589831 in Participants with Advanced Solid Tumors

2023-503170-20-00 Protocol BP44474 Human pharmacology (Phase I) - First administration to humans Not authorised

Status Not authorised · 4 EU/EEA countries · 9 sites · Protocol BP44474

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Not authorised
Participants planned 49
Countries 4
Sites 9

Advanced solid tumors

Key facts

Sponsor
F. Hoffmann-La Roche AG
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Decision date (initial)
2023-11-23
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced solid tumors

VersionLevelCodeTermSystem organ class
21.0 LLT 10080676 Microsatellite instability 10010331
22.0 PT 10078672 DNA mismatch repair protein gene mutation 100000004850
21.0 LLT 10049280 Solid tumour 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

F. Hoffmann-La Roche AG

Sponsor organisation
F. Hoffmann-La Roche AG
Address
Grenzacherstrasse 124
City
Basel
Postcode
4058
Country
Switzerland

Scientific contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Head of CTRM Clinical Trial Regulatory Management, Product Development Regulatory

Public contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Head of CTRM Clinical Trial Regulatory Management, Product Development Regulatory

Locations

4 EU/EEA countries · 9 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Not authorised 8 1
Denmark Not authorised 8 1
France Not authorised 10 2
Spain Not authorised 20 5
Rest of world
Canada, United Kingdom, United States
3

Investigational sites

Belgium

1 site · Not authorised
UZ Leuven
General Medical Oncology, Herestraat 49, 3000, Leuven

Denmark

1 site · Not authorised
Rigshospitalet
Rigshospitalet; Fase 1 Enhed - Onkologi, Blegdamsvej 9, 2100, Copenhagen Oe

France

2 sites · Not authorised
Centre Leon Berard
Medical Oncology, 28 Rue Laennec, 69008, Lyon
Institut Gustave Roussy
Medical Oncology - DITEP, 114 Rue Edouard Vaillant, 94800, Villejuif

Spain

5 sites · Not authorised
Hospital Universitari Vall D Hebron
Servicio de Oncología, Edificio Materno-Infantil, Passeig De La Vall D'hebron 119-129, Barcelona
Clinica Universidad De Navarra
Servicio de Oncología, Calle Marquesado De Santa Marta 1, 28027, Madrid
Clinica Universidad De Navarra
Servicio de Oncología, Avenue Pio XII 36, 31008, Pamplona
Hospital Clinico Universitario De Valencia
Servicio de Oncología, Avenida Blasco Ibanez 17, 46010, Valencia
Hospital Universitario Hm Sanchinarro
Servicio de Oncología, Calle Ona 10, 28050, Madrid

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-08-21 Denmark Not acceptable
2023-11-20
2023-11-21